Cell Dissociation Market to reach $1.7 Billion by 2030; growing demand for cell therapy, increasing investment in cell-based research & growth of pharmaceutical & biotechnological industries drives the need for Cell Dissociation

The Cell Dissociation Market size is estimated to reach $1.7 Billion by 2030, growing at a CAGR of 16.3% during the forecast period 2024-2030, according to a recent report published by IndustryARC, titled, “ Cell Dissociation – Cell Dissociation Market – By Method (Mechanical Dissociation, Enzymatic Dissociation and Chemical Dissociation), By Product (Enzymes, Chemicals Instruments & Accessories), By Application (Stem Cell Research, Cancer Research, Tissue Engineering, Immunology, Regenerative Medicine, Drug Discovery & Development, Gene Therapy and Others), By End User (Pharmaceutical & Biotechnology Companies, Research & Academic Institutes, Contract Research Organizations (CROs), Hospitals and Diagnostic Labs and Others), By Geography - Global Opportunity Analysis & Industry Forecast, 2024-2030 and By Geography Global Opportunity Analysis & Industry Forecast, 2024-2030.”

The growing interest in cell therapy is the primary driver of the market. The increasing investment in cell-based research boosts the market. Additionally, the growth of pharmaceutical & biotechnological industries further drives the market.

North America accounted for the largest share of 36% of the Cell Dissociation Market in 2023. The robust healthcare infrastructure, substantial research investments and favourable regulatory environment propels the demand for Cell Dissociation. The region has a long history of pioneering research in cell biology with numerous world-renowned universities and research centers. This strong foundation has led to the development of innovative cell dissociation technologies and techniques. Additionally, North America's favorable regulatory environment and access to venture capital funding have fostered a thriving biotechnology ecosystem supporting the growth of cell dissociation companies and research initiatives. In March 2022,

Invest Ontario announced support for OmniaBio Inc. in launching a new biomanufacturing facility that will advance pioneering medicine for various diseases. OmniaBio, a Canadian cell and gene therapy contract development and manufacturing organization (CDMO), will support a broad range of cell and gene therapy companies by providing process development and clinical/commercial production services. Furthermore, the presence of major pharmaceutical and biotechnology companies in the region creates a strong demand for cell dissociation technologies, driving their development and adoption.

 Growing Interest in Cell-Based Research

Rising investments in cell-based research are a key driver in the expansion of the cell dissociation market. Governments, academic institutions and private companies are pouring resources into research areas like regenerative medicine, immunotherapy and stem cell therapies all of which rely heavily on cell dissociation. The growing emphasis on personalized medicine and innovative cell-based treatments is accelerating funding into technologies that facilitate single-cell isolation and analysis. For instance, in March 2022, Deepcell, a life science company pioneering AI-powered single cell classification and isolation for basic and translational research, announced that it has closed its $73 million Series B round of financing. The new funding will allow Deepcell to continue product development and enable early commercial introduction of a new standard for obtaining biological insights from single cell analysis. The influx of investments is leading to the development of more efficient and advanced dissociation techniques, enabling high-throughput workflows and better outcomes in scientific studies, further fueling growth in the market.

Drug discovery is the fastest growing application for cell dissociation due to the rising need for high-throughput screening of potential therapeutics. Pharmaceutical and biotech companies rely on effective cell dissociation techniques to isolate individual cells for testing drug efficacy, toxicity and cellular response. For instance, Curi Bio, a US based startup, develops human stem cell-based platforms for drug discovery Single-cell analysis, enabled by proper cell dissociation, allows researchers to study the heterogeneity of cell populations and identify unique drug targets. Dissociated cells are used to simulate drug reactions on a cellular level leading to the discovery of more targeted and effective treatments. This trend is driving rapid growth in the use of cell dissociation in drug discovery.

Key companies profiled in the Cell Dissociation Market are Thermo Fisher Scientific, Corning Incorporated, BD, F Hoffmann-La Roche Ltd, GE Healthcare, Himedia Laboratory, Merck KGaA, Miltenyi Biotec, Sartorius AG, Danaher Corporation and others

Tissue Banking Market- Tissue Banking Market Size is forecast to reach $61,629.76 million by 2030, at a CAGR of 4% during the forecast period 2024-2030. owing to a rise in tissue transplant cases and rising incidences of cancers, cardiovascular diseases, and diabetes.

Cell Isolation/Cell Separation Market- Cell Isolation/Cell Separation Market size is estimated to reach $14.4Bn by 2025, growing at a CAGR of 17.61% during the forecast period 2020-2025. The market is being driven primarily by increase in the research activities in the pharmaceutical and biotechnological industries. 

Stem Cell Market – Stem Cell market size is forecast to reach $16.8 billion by 2026, growing at a CAGR of 9.4% during the forecast period 2021-2026. Increasing research activities on stem cells and increasing approvals of GMP certified facilities are the major factors driving the growth of the market.